Stefanie Hauck

Title: Stefanie Hauck: Innovator in Cancer Treatment

Introduction

Stefanie Hauck is a prominent inventor based in Munich, Germany. She has made significant contributions to the field of cancer research through her innovative work on monoclonal antibodies. Her research focuses on developing targeted therapies that can improve treatment outcomes for cancer patients.

Latest Patents

Stefanie Hauck holds a patent for an "Anti-CD73 monoclonal antibody, encoding nucleic acids and method for producing." This invention relates to improved anti-CD73 antibodies that bind to a membrane-bound form of the CD73 protein, which plays a cancer-promoting role. The antibodies inhibit the enzymatic activity of this protein while not affecting the soluble form of CD73 involved in cardioprotection. The patent also covers methods for generating these specific antibodies and their uses as medicaments in cancer treatment, amelioration, prophylaxis, and diagnostics.

Career Highlights

Stefanie Hauck is associated with the Helmholtz Zentrum München, Deutsches Forschungszentrum für Gesundheit und Umwelt. Her work at this esteemed research institution has positioned her as a leader in the development of innovative cancer therapies.

Collaborations

Stefanie collaborates with notable colleagues, including Regina Feederle and Bettina Von Neubeck, who contribute to her research efforts and enhance the impact of her work in the scientific community.

Conclusion

Stefanie Hauck's contributions to cancer research through her patented innovations highlight her role as a key figure in the development of targeted therapies. Her work promises to advance the field and improve patient outcomes in cancer treatment.